

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 9/12, 15/54, 15/62, G01N 33/53</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/33962</b> <b>(43) International Publication Date:</b> 8 July 1999 (08.07.99)
<b>(21) International Application Number:</b> PCT/US98/27666 <b>(22) International Filing Date:</b> 28 December 1998 (28.12.98)  <b>(30) Priority Data:</b> 60/068,960 30 December 1997 (30.12.97) US  <b>(71) Applicant:</b> CHIRON CORPORATION [US/US]; 4560 Horton Street – R440, Emeryville, CA 94608 (US).  <b>(72) Inventors:</b> REINHARD, Christoph; Chiron Corporation, Intellectual Property – R440, P.O. Box 8097, Emeryville, CA 94662–8097 (US). POT, David; Chiron Corporation, Intellectual Property – R440, P.O. Box 8097, Emeryville, CA 94662–8097 (US). KASSAM, Altaf; Chiron Corporation, Intellectual Property – R440, P.O. Box 8097, Emeryville, CA 94662–8097 (US). MARENBACH, Tasha; Chiron Corporation, Intellectual Property – R440, P.O. Box 8097, Emeryville, CA 94662–8097 (US). WILLIAMS, Lewis, T.; Chiron Corporation, Intellectual Property – R440, P.O. Box 8097, Emeryville, CA 94662–8097 (US).  <b>(74) Agents:</b> POTTER, Jane, E., R. et al.; Chiron Corporation, Intellectual Property – R440, P.O. Box 8097, Emeryville, CA 94662–8097 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> HUMAN CYCLIN-DEPENDENT KINASE ( <i>hPFTAIRE</i> )		
<b>(57) Abstract</b>  A human gene encoding a novel cyclin-dependent kinase termed <i>hPFTAIRE</i> and its expression products can be used to provide reagents and methods for detecting migrating or metastasizing cells. Compositions and methods for treating proliferative disorders and neoplasia are also provided.		















































































































